SRR12202446
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.460
- KRAS_SIGNALING_DN+0.320
- HEDGEHOG_SIGNALING+0.290
- COAGULATION+0.260
- INFLAMMATORY_RESPONSE+0.230
- ANGIOGENESIS+0.210
- UV_RESPONSE_DN+0.210
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.200
- SPERMATOGENESIS+0.180
- IL6_JAK_STAT3_SIGNALING+0.150
Top 10 suppressed
- MYC_TARGETS_V2-0.660
- E2F_TARGETS-0.650
- MYC_TARGETS_V1-0.620
- G2M_CHECKPOINT-0.560
- CHOLESTEROL_HOMEOSTASIS-0.520
- UNFOLDED_PROTEIN_RESPONSE-0.490
- MTORC1_SIGNALING-0.480
- DNA_REPAIR-0.440
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.410
- GLYCOLYSIS-0.390
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12202442 | — | — | 0.932 |
| 2 | AUR-AD9J-TTP1-B-4-0-R-A584-39 | — | D | 0.918 |
| 3 | MNG1135 | — | — | 0.917 |
| 4 | TCGA-FJ-A3Z7-01A-12R-A23N-07 | — | — | 0.916 |
| 5 | TCGA-75-7025-01A-12R-1949-07 | — | cohortA1 | 0.908 |
| 6 | MDT-AP-2478 | Med | Medulloblastoma | 0.908 |
| 7 | SRR12202400 | — | — | 0.900 |
| 8 | SRR12202435 | — | — | 0.899 |
| 9 | DRR168582 | — | — | 0.899 |
| 10 | MNG1123 | — | — | 0.891 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.460 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.320 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.290 | Inavolisib | — uncovered |
| COAGULATION | 0.260 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.230 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.210 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.210 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.200 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.180 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.150 | Inavolisib | — uncovered |
| COMPLEMENT | 0.140 | Inavolisib | — uncovered |
| MYOGENESIS | 0.130 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.130 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.120 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.080 | Idelalisib | — uncovered |